bdawg
Member
Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. - PubMed - NCBI
This study suggests that Androsterone, when it activates the FxR, reduces glucoronidation of androgens n prostate-cancer cells.
Glucoronated androgen-conjugates seem to inactivate the androgens, and reducing the conjugation is therefore protective against cancer - not surprisingly so.
I wouldnt say its a great thing - keeping DHT active in the prostate is playing with fire. Normally DHT gets broken down into androsterone and 3alphadiol in the prostate which have weak AR affinity, which might be why elevated blood DHT levels dont necessarily lead to prostate cancer risk
"It is suggested that the conjugating activity of UGT enzymes in androgen target tissues is a mechanism for modulating the action of steroids and/or protecting the tissues from deleterious high concentrations of androgens."
Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. - PubMed - NCBI